This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Bone Marrow Transplantation  • Dermatologic Procedures, Other  • Drug Therapy  • Drug Therapy, Other  • Hematology/ Hematologic Malignancies  • Leukemias/ Lymphomas  • Immunology  • Immunologic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Juan A. Moreno-Romero, MD; Francesc Fernández-Avilés, MD; Enric Carreras, MD; Montserrat Rovira, MD; Carmen Martínez, MD; José M. Mascaró Jr, MD

Arch Dermatol. 2008;144(9):1106-1109.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

INTRODUCTION

Chronic graft-vs-host disease (GVHD) remains the most common late complication of allogeneic hematopoietic stem cell transplantation (HSCT), despite improvements in its prophylaxis. Although the graft-vs-leukemia effect associated with the development of chronic GVHD may be beneficial in controlling the underlying disease, patients with chronic GVHD are prone to fatal infections owing to multiple abnormalities of their reconstructed immune systems. Infection is the most common cause of death in patients with chronic GVHD. Chronic GHVD may also compromise a patient's quality of life as a result of long-term immunosuppressive therapy and the symptoms of GVHD itself. Chronic GVHD appears to be one of the major determinants in the survival and quality of life of patients after allogeneic HSCT.¹

Sclerodermatous GVHD is a rare form of chronic GVHD, with a prevalence . . . [Full Text of this Article]

REPORT OF A CASE

THERAPEUTIC CHALLENGE

SOLUTION

COMMENT

AUTHOR INFORMATION

Department of Dermatology (Drs Moreno-Romero and Mascaró) and Bone Marrow Transplant Unit, Department of Hematology (Drs Fernández-Avilés, Carreras, Rovira, and Martínez), Hospital Clínic, University of Barcelona, and Department of Dermatology, Hospital General de Catalunya (Dr Moreno-Romero), Barcelona, Spain

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease
Magro et al.
Blood 2009;114:719-722.
ABSTRACT | FULL TEXT  

A Call for More Dermatologic Input Into Chronic Graft-vs-Host Disease Clinical Trials
Cowen
Arch Dermatol 2009;145:337-338.
FULL TEXT  

Briefly Noted
Journal Watch Dermatology 2009;2009:4-4.
FULL TEXT